# Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers

**Authors:** Memoona Shaukat, Ekkehard Grünig, Simon Haas, Jan Haas, Mohammad Panahi, Martin Granzow, Tobias J. Lange, Stefan Stadler, Natascha Sommer, Peter Dorfmüller, Benjamin Meder, Satenik Harutyunova, Benjamin Egenlauf, Panagiota Xanthouli, Katrin Hinderhofer, Christina A. Eichstaedt

PMC · DOI: 10.1038/s41598-025-34167-0 · 2026-01-29

## TL;DR

This study explores new genetic and environmental factors in heritable pulmonary arterial hypertension beyond known genes.

## Contribution

The study identifies novel genetic variants and environmental exposures potentially linked to heritable pulmonary arterial hypertension.

## Key findings

- Pathogenic variants in CYBA, FKBP1A, and PTGR2 genes were found in some HPAH families.
- Exposure to trichloroethylene, asbestos, and tramadol was reported in families with PAH.
- Environmental triggers may contribute to HPAH alongside genetic predisposition.

## Abstract

Our goal was to identify new environmental or genetic causes in heritable pulmonary arterial hypertension (HPAH) families outside the 18 known diagnostics PAH genes. PAH gene panel sequencing was performed for 47 HPAH families which revealed pathogenic variants in 39 families. Five of the remaining families agreed to whole exome sequencing and to fill in a drug and toxin exposure questionnaire. In Family 1 and 2, mother and daughter with HPAH carried a likely pathogenic variant in the CYBA gene and a variant of uncertain significance in the FKBP1A gene, respectively, following ACMG guidelines. In Family 3, we detected a likely pathogenic variant in the PTGR2 gene. These genes could play part in PAH pathogenesis but further functional analyses are required to corroborate these findings. In the remaining two families, we could not identify any plausible genetic cause. However, a father and son with PAH reported exposure to trichloroethylene, asbestos and tramadol in Family 4. In Family 5, two brothers with pulmonary veno-occlusive disease showed occupational toxin exposure. Thus, our findings indicate that not only a genetic predisposition but also environmental triggers should be investigated for HPAH patients.

The online version contains supplementary material available at 10.1038/s41598-025-34167-0.

## Linked entities

- **Genes:** CYBA (cytochrome b-245 alpha chain) [NCBI Gene 1535], FKBP1A (FKBP prolyl isomerase 1A) [NCBI Gene 2280], PTGR2 (prostaglandin reductase 2) [NCBI Gene 145482]
- **Chemicals:** trichloroethylene (PubChem CID 6575), tramadol (PubChem CID 19472)
- **Diseases:** pulmonary arterial hypertension (MONDO:0015924), pulmonary veno-occlusive disease (MONDO:0009937)

## Full-text entities

- **Genes:** MIR140 (microRNA 140) [NCBI Gene 406932] {aka MIRN140, SEDN, miRNA140, mir-140}, CYBA (cytochrome b-245 alpha chain) [NCBI Gene 1535] {aka CGD4, p22-PHOX}, KCNA5 (potassium voltage-gated channel subfamily A member 5) [NCBI Gene 3741] {aka ATFB7, HCK1, HK2, HPCN1, KV1.5, PCN1}, BMPR1B (bone morphogenetic protein receptor type 1B) [NCBI Gene 658] {aka ALK-6, ALK6, AMD3, AMDD, BDA1D, BDA2}, EIF2AK4 (eukaryotic translation initiation factor 2 alpha kinase 4) [NCBI Gene 440275] {aka GCN2, PVOD2}, NPR2 (natriuretic peptide receptor 2) [NCBI Gene 4882] {aka AMDM, ANPRB, ANPb, ECDM, GC-B, GCB}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, KLF2 (KLF transcription factor 2) [NCBI Gene 10365] {aka LKLF}, CAV1 (caveolin 1) [NCBI Gene 857] {aka BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21}, TBX4 (T-box transcription factor 4) [NCBI Gene 9496] {aka ICPPS, PAPPAS, SPS}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, GDF2 (growth differentiation factor 2) [NCBI Gene 2658] {aka BMP-9, BMP9, HHT5}, FKBP1A (FKBP prolyl isomerase 1A) [NCBI Gene 2280] {aka FKBP-12, FKBP-1A, FKBP1, FKBP12, PKC12, PKCI2}, ATP13A3 (ATPase 13A3) [NCBI Gene 79572] {aka AFURS1, PPH5}, ABCC8 (ATP binding cassette subfamily C member 8) [NCBI Gene 6833] {aka ABC36, HHF1, HI, HRINS, MODY12, MRP8}, PTGR2 (prostaglandin reductase 2) [NCBI Gene 145482] {aka HEL-S-298, PGR2, ZADH1}, ENG (endoglin) [NCBI Gene 2022] {aka END, HHT1, ORW1}, KCNK3 (potassium two pore domain channel subfamily K member 3) [NCBI Gene 3777] {aka DDSA, K2p3.1, OAT1, PPH4, TASK, TASK-1}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, AQP1 (aquaporin 1 (Colton blood group)) [NCBI Gene 358] {aka AQP-CHIP, CHIP28, CO}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, Cyba (cytochrome b-245, alpha polypeptide) [NCBI Gene 13057] {aka b558, nmf333, p22-phox, p22phox}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, PAH (phenylalanine hydroxylase) [NCBI Gene 5053] {aka PH, PKU, PKU1}, SOX17 (SRY-box transcription factor 17) [NCBI Gene 64321] {aka PPH7, VUR3}, SMAD9 (SMAD family member 9) [NCBI Gene 4093] {aka MADH6, MADH9, PPH2, SMAD8, SMAD8/9, SMAD8A}, BMPR2 (bone morphogenetic protein receptor type 2) [NCBI Gene 659] {aka BMPR-II, BMPR3, BMR2, BRK-3, POVD1, PPH1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ACVRL1 (activin A receptor like type 1) [NCBI Gene 94] {aka ACVRLK1, ALK-1, ALK1, HHT, HHT2, ORW2}
- **Diseases:** acromesomelic dysplasia (MESH:C535658), PH (MESH:D006976), PVOD (MESH:D011668), AD (MESH:D000544), death (MESH:D003643), DD (MESH:C536170), right heart failure (MESH:D006333), hypothyroidism (MESH:D007037), hypoxemia (MESH:D000860), Pulmonary arterial hypertension (MESH:D000081029), hypertrophy (MESH:D006984), CTD (MESH:D003240), telangiectasias (MESH:D013684), Dyslipidemia (MESH:D050171), pulmonary venous congestion (MESH:D006940), hypercholesterolemia (MESH:D006937), inflammation (MESH:D007249), hyperlipidemia (MESH:D006949), HPAH (MESH:D065627), ILD (MESH:D017563), remodelling (MESH:D020257), dyspnea (MESH:D004417), right ventricular dysfunction (MESH:D018497), pulmonary fibrosis (MESH:D011658), venous thrombosis (MESH:D020246), chronic granulomatous disease (MESH:D006105), hypoxic (MESH:D002534), Raynaud's syndrome (MESH:D011928), fibrosis (MESH:D005355), congestion (MESH:D002311), tumor drugs (MESH:D009369), Mendelian Inheritance in Man (MESH:D030342), systemic sclerosis (MESH:D012595)
- **Chemicals:** Tramadol (MESH:D014147), EDTA (MESH:D004492), strontium-90 (MESH:C000615490), carbon (MESH:D002244), ROS (MESH:D017382), eosin (MESH:D004801), asbestos (MESH:D001194), molecular oxygen (MESH:D010100), amlodipine (MESH:D017311), sildenafil (MESH:D000068677), cholesterol (MESH:D002784), hematoxylin (MESH:D006416), carbon dioxide (MESH:D002245), benzene (MESH:D001554), paraffin (MESH:D010232), serotonin (MESH:D012701), ambrisentan (MESH:C467894), mineral oil (MESH:D008899), NADPH (MESH:D009249), triglycerides (MESH:D014280), plutonium (MESH:D011005), PGI2 (MESH:D011464), PO2 (MESH:C093415), carbon monoxide (MESH:D002248), guanosine triphosphate (MESH:D006160), superoxide (MESH:D013481), lipid (MESH:D008055), PGE2 (MESH:D015232), prostaglandin (MESH:D011453), cGMP (MESH:D006152), L-tryptophan (MESH:D014364), FK506 (MESH:D016559), cobalt-60 (MESH:C000615395), 's Wort (-), cesium-134 (MESH:C000614987), rapeseed oil (MESH:D000074262), trichloroethylene (MESH:D014241)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.300 C > G, c.300C > Gp. (Phe100Leu), c.934C > Tp.(Arg312Cys), c.934C > T, rs145655340, c.203 + 1G > C, Phe100Leu

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12858969/full.md

---
Source: https://tomesphere.com/paper/PMC12858969